Global Health Council v. Donald J. Trump

District Court, District of Columbia·Decided February 26, 2025·No. Civil Action No. 2025-0402·Published

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

AIDS VACCINE ADVOCACY COALITION, et al.,

Plaintiffs, Civil Action No. 25-00400 (AHA) v.

UNITED STATES DEPARTMENT OF STATE, et al.,

Defendants.

GLOBAL HEALTH COUNCIL, et al.,

Plaintiffs, Civil Action No. 25-00402 (AHA) v.

DONALD J. TRUMP, et al.,

Defendants.

Order Denying Motion To Stay Pending Appeal

On February 13, 2025, this Court granted a temporary restraining order (“TRO”), finding

Plaintiffs had shown that Defendants’ blanket suspension of congressionally appropriated foreign

aid funds would cause them irreparable harm and was likely arbitrary and capricious under the

Administrative Procedure Act (“APA”) for failing to consider the immense reliance interests at

stake. Glob. Health, ECF No. 21; AIDS Vaccine, ECF No. 17. While the Court did not grant

Plaintiffs the full scope of emergency relief they sought, it enjoined Defendants from continuing a

blanket freeze of the congressionally appropriated funds. Over the nearly two weeks since,

Plaintiffs have moved multiple times to enforce the Court’s TRO and hold Defendants in contempt, each time attaching evidence that Defendants have continued their funding freeze and evidence of

the irreparable harm to businesses and organizations across the country that justified the TRO. In

response to those motions, the Court declined to hold Defendants in contempt and reaffirmed

certain flexibility and authority Defendants reserved, consistent with the TRO. AIDS Vaccine, ECF

No. 30; AIDS Vaccine, Feb. 25, 2025, Min. Entry; see also AIDS Vaccine, ECF No. 34 (addressing

Defendants’ motion for clarification). However, the Court twice reiterated in its orders: “[T]o the

extent Defendants have continued the blanket suspension, they are ordered to immediately cease

it and to take all necessary steps to honor the terms of contracts, grants, cooperative agreements,

loans, and other federal foreign assistance awards that were in existence as of January 19, 2025,

including but not limited to disbursing all funds payable under those terms.” AIDS Vaccine, ECF

No. 34 at 5; AIDS Vaccine, ECF No. 30 at 5. The Court’s TRO and these subsequent orders remain

in effect and unchallenged. Neither Defendants’ recent notice of appeal nor the instant motion to

stay pending appeal challenges the terms of the TRO or these prior orders.

Defendants have filed the instant motion to stay the Court’s order granting Plaintiffs’ latest

motions to enforce the TRO. In those motions, Plaintiffs again provided evidence that Defendants

have simply continued their blanket funding freeze and further documentation of the irreparable

harm they are suffering, including attestations of severe harm that will manifest before the end of

the week. Plaintiffs explained that they tailored their motion to enforce to address only the most

acute irreparable harm, seeking compliance with the TRO by unfreezing the congressionally

appropriated funds at least for all work completed prior to February 13, the date of the Court’s

TRO. Upon receiving the motion, and now twelve days since the TRO had been granted, the Court

held a prompt hearing to hear from all parties in both cases on the state of compliance. At the

hearing, counsel for Defendants acknowledged that the Court’s TRO foreclosed Defendants from

2 giving any effect to suspensions or terminations that were issued before February 13. AIDS

Vaccine, ECF No. 35 at 33–34. The Court asked counsel for Defendants if he was “aware of steps

taken to actually release those funds,” consistent with the TRO and subsequent orders. Id. at 35.

Counsel responded that he was “not in a position to answer that.” Id. For this and additional reasons

stated on the record, the Court orally granted Plaintiffs’ second round of motions to enforce the

TRO. The Court ordered Defendants to unfreeze funds for work completed prior to February 13,

consistent with the terms of the TRO and the Court’s subsequent orders, giving Defendants an

additional 36 hours to do so. The Court made clear that, although it was focusing on this specific

aspect of the TRO that was the subject of Plaintiffs’ motion to enforce and which was a

consequence of the TRO’s injunctive relief, the Court was “in no way limiting the scope of the

TRO or modifying its terms.” Id. at 55–56. The Court further ordered the parties to provide a joint

status report the next day, updating the Court on the circumstances and providing documentation

necessary for the parties and Court to assess the state of compliance.

Defendants’ principal basis for staying the Court’s ruling pending appeal appears to be that

they can only partially unfreeze funds within the additional 36 hours that the Court gave them, and

that they need more time to unfreeze the funds at issue in Plaintiffs’ latest motion to enforce. See

AIDS Vaccine, ECF No. 37 at 2–3 (stating it is “not possible for Defendants to comply” within 36

hours). This is not something that Defendants have previously raised in this Court, whether at the

hearing or any time before filing their notice of appeal and seeking a stay pending appeal. That is

so even though Plaintiffs’ motion to enforce explicitly proposed compliance on this time frame. If

Defendants wanted to propose a different schedule for achieving compliance, that is something

they could have proposed to this Court and that the Court could have considered alongside

Plaintiffs’ showings. Any such schedule would have to take into account that Defendants have

3 already had nearly two weeks to come into compliance, apparently without taking any meaningful

steps to unfreeze funds. Moreover, particularly given Defendants’ delay and the imminent harm

Plaintiffs have documented, it would require far greater specificity than has been provided in the

motion to stay pending appeal, including significant, concrete steps in the immediate term toward

reaching compliance. This is not nearly grounds for a stay pending appeal—to the contrary, a stay

would directly contradict that purpose.

Defendants’ remaining arguments in the motion for stay pending appeal demonstrate the

shifting ground at this early stage and simply highlight the need for expeditious resolution of the

preliminary injunction motions in these cases, which the Court has agreed to consider on the

parties’ proposed briefing schedule. Defendants state, for instance, that injunctive relief here

“intrudes deeply into the prerogatives of the Executive Branch and the discretion committed to the

President under Article II,” asserting that “Executive Branch leadership harbors concerns about

the possibility of waste and fraud and is in the process of developing revised payment processing

systems to address those concerns.” AIDS Vaccine, ECF No. 37 at 4. But the blanket suspension

of congressionally appropriated funding that has been challenged and temporarily enjoined was

the result of a categorical order, not any specific finding “about the possibility of waste and fraud.”

Indeed, in defending the challenged action at the Court’s TRO hearing, Defendants did not even

attempt to argue that the agency action was or could be justified based on waste or fraud. And, to

date, Defendants have not adduced any evidence “about the possibility of waste and fraud” beyond

conclusory statements like the one in their motion.

Free access — add to your briefcase to read the full text and ask questions with AI

Global Health Council v. Donald J. Trump, (D.D.C. 2025).

Global Health Council v. Donald J. Trump (Global Health Council v. Donald J. Trump) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Padilla Robles v. Kerry
74 F. Supp. 3d 254 (District of Columbia, 2014)
Zivotofsky v. Kerry
576 U.S. 1 (Supreme Court, 2015)